{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:36:23Z","timestamp":1791765383873,"version":"4.3.4"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","annalsofvascularsurgery.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Vascular Surgery"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.avsg.2023.12.071","type":"journal-article","created":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T21:22:31Z","timestamp":1708464151000},"page":"47-57","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["The Use and Impact of Cilostazol on Patients Undergoing Endovascular Peripheral Interventions"],"prefix":"10.1016","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3160-9938","authenticated-orcid":false,"given":"Dana","family":"Alameddine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fachreza Aryo","family":"Damara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Pinto Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Huttler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin D.","family":"Slade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isibor","family":"Arhuidese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edouard","family":"Aboian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassius Iyad","family":"Ochoa Chaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.avsg.2023.12.071_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta15400","article-title":"A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease","volume":"15","author":"Squires","year":"2011","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.avsg.2023.12.071_bib2","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s10557-021-07187-x","article-title":"Cilostazol: a review of basic mechanisms and clinical uses","volume":"36","author":"Kherallah","year":"2022","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.avsg.2023.12.071_bib3","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.018184","article-title":"Efficacy and safety of adjunctive cilostazol to clopidogrel-treated diabetic patients with symptomatic lower extremity artery disease in the prevention of ischemic vascular events","volume":"10","author":"Kalantzi","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.avsg.2023.12.071_bib4","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.thromres.2014.05.040","article-title":"Cilostazol and outcome in outpatients with peripheral artery disease","volume":"134","author":"Perez","year":"2014","journal-title":"Thromb Res"},{"key":"10.1016\/j.avsg.2023.12.071_bib5","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0741-5214(98)70357-X","article-title":"Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease","volume":"27","author":"Money","year":"1998","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.avsg.2023.12.071_bib6","doi-asserted-by":"crossref","first-page":"NP1","DOI":"10.1177\/1358863X17701592","article-title":"2016 AHA\/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary","volume":"22","author":"Gerhard-Herman","year":"2017","journal-title":"Vasc Med"},{"key":"10.1016\/j.avsg.2023.12.071_bib7","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1177\/1358863X19838327","article-title":"Outcomes with cilostazol after endovascular therapy of peripheral artery disease","volume":"24","author":"Megaly","year":"2019","journal-title":"Vasc Med"},{"key":"10.1016\/j.avsg.2023.12.071_bib8","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jacc.2008.09.020","article-title":"Efficacy of cilostazol after endovascular therapy for femoropopliteal artery disease in patients with intermittent claudication","volume":"53","author":"Soga","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.avsg.2023.12.071_bib9","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ejvs.2012.09.020","article-title":"Impact of cilostazol on angiographic restenosis after balloon angioplasty for infrapopliteal artery disease in patients with critical limb ischemia","volume":"44","author":"Soga","year":"2012","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.avsg.2023.12.071_bib10","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.jvs.2011.06.024","article-title":"Impact of cilostazol after endovascular treatment for infrainguinal disease in patients with critical limb ischemia","volume":"54","author":"Soga","year":"2011","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.avsg.2023.12.071_bib11","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1177\/0003319714551361","article-title":"Effect of cilostazol following endovascular intervention for peripheral artery disease","volume":"66","author":"Nanto","year":"2015","journal-title":"Angiology"},{"key":"10.1016\/j.avsg.2023.12.071_bib12","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1161\/CIRCULATIONAHA.112.000711","article-title":"Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study","volume":"127","author":"Iida","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.avsg.2023.12.071_bib13","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1001\/jamasurg.2017.3942","article-title":"Association of quality improvement registry participation with appropriate follow-up after vascular procedures","volume":"153","author":"Brooke","year":"2018","journal-title":"JAMA Surg"},{"key":"10.1016\/j.avsg.2023.12.071_bib14","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1053\/j.semvascsurg.2015.09.003","article-title":"Using the Vascular Quality Initiative to improve quality of care and patient outcomes for vascular surgery patients","volume":"28","author":"Bensley","year":"2015","journal-title":"Semin Vasc Surg"},{"key":"10.1016\/j.avsg.2023.12.071_bib15","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jvs.2014.11.067","article-title":"Cilostazol and freedom from amputation after lower extremity revascularization","volume":"61","author":"Neel","year":"2015","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.avsg.2023.12.071_bib16","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jvs.2008.02.062","article-title":"Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions","volume":"48","author":"Iida","year":"2008","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.avsg.2023.12.071_bib17","doi-asserted-by":"crossref","first-page":"e371","DOI":"10.1016\/j.ijcard.2013.12.295","article-title":"Cilostazol enhances mobilization and proliferation of endothelial progenitor cells and collateral formation by modifying vasculo-angiogenic biomarkers in peripheral arterial disease","volume":"172","author":"Chao","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.avsg.2023.12.071_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0132835","article-title":"Cilostazol induces PGI2 production via activation of the downstream epac-1\/rap1 signaling cascade to increase intracellular calcium by PLC\u03b5 and to activate p44\/42 MAPK in human aortic endothelial cells","volume":"10","author":"Hashimoto","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.avsg.2023.12.071_bib19","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/j.jvs.2013.11.096","article-title":"Cilostazol is associated with improved outcomes after peripheral endovascular interventions","volume":"59","author":"Warner","year":"2014","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.avsg.2023.12.071_bib20","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.avsg.2020.05.040","article-title":"The reintervention index: a new outcome measure for comparative effectiveness of lower extremity revascularization","volume":"69","author":"Ochoa Chaar","year":"2020","journal-title":"Ann Vasc Surg"},{"key":"10.1016\/j.avsg.2023.12.071_bib21","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/ccd.23304","article-title":"Restenosis after stent implantation for superficial femoral artery disease in patients treated with cilostazol","volume":"79","author":"Soga","year":"2012","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.avsg.2023.12.071_bib22","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/S0002-9149(02)02869-2","article-title":"Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication","volume":"90","author":"Thompson","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.avsg.2023.12.071_bib23","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jvs.2007.10.009","article-title":"Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: a Study in Long-term Effects)","volume":"47","author":"Hiatt","year":"2008","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.avsg.2023.12.071_bib24","unstructured":"E.M. Agency, European Medicines Agency recommends restricting use of cilostazol-containing medicines, Available at: https:\/\/www.ema.europa.eu\/en\/news\/european-medicines-agency-recommends-restricting-use-cilostazol-containing-medicines (March 6, 2024)."}],"container-title":["Annals of Vascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890509624000578?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890509624000578?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T15:46:57Z","timestamp":1715010417000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890509624000578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":24,"alternative-id":["S0890509624000578"],"URL":"https:\/\/doi.org\/10.1016\/j.avsg.2023.12.071","relation":{},"ISSN":["0890-5096"],"issn-type":[{"value":"0890-5096","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Use and Impact of Cilostazol on Patients Undergoing Endovascular Peripheral Interventions","name":"articletitle","label":"Article Title"},{"value":"Annals of Vascular Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.avsg.2023.12.071","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}